Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
m (Aidan moved page Multidrug resistance Gram-negative bacteria to Multidrug-resistant Gram-negative bacteria without leaving a redirect) |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
* Defined by the European CDC<ref>Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. ''Clin Microbiol Infect''. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988.</ref> as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism |
|||
* Refer to to [[Multidrug-resistant organism|multidrug-resistant organisms]] for specific |
|||
==Management== |
==Management== |
||
| Line 6: | Line 11: | ||
**Adds coverage of some carbapenemases and AmpC |
**Adds coverage of some carbapenemases and AmpC |
||
*[[Fosfomycin]] |
*[[Fosfomycin]] |
||
** |
|||
*[[Colistin]] |
*[[Colistin]] |
||
** |
|||
*[[Cefiderocol]]: available through Special Access Program as well as preapproval by manufacturer |
*[[Cefiderocol]]: available through Special Access Program as well as preapproval by manufacturer |
||
*[[Meropenem-vaborbactam]]: still awaiting Health Canada Drug Review |
*[[Meropenem-vaborbactam]]: still awaiting Health Canada Drug Review |
||
Revision as of 21:18, 2 October 2022
Background
- Defined by the European CDC[1] as non-susceptibility to at least one agent in three or more categories of antimicrobials, with the categories varying by organism
- Refer to to multidrug-resistant organisms for specific
Management
- Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
- Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
- ↑ Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988.
References
- ^ A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, D.L. Monnet. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
